Compare VNET Group Inc (VNET) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VNET Group Inc vs Viatris Inc — how do they compare? VNET Group Inc trades at $7.7 (market cap $2.19B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 9× VNET Group Inc's market cap, and Viatris Inc pays a 2.83% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| VNET | VTRS | |
|---|---|---|
Market Cap | $2.19B | $19.79B |
Sector | Technology | Health |
52-Week High | $14.03 | $17.39 |
52-Week Low | $7.34 | $8.74 |
Enterprise Value | $5.32B | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNET trades at $7.675, up 3.86% today, but faces bearish technical signals with 15 sell indicators against 0 buys. The company reported a Q1 2026 net loss of $1.20 per share, missing estimates, while revenue reached $390.13 million. Despite negative profitability margins, analyst consensus remains 62.5% buy-rated, citing strategic investor entry and AI-driven data center demand as growth catalysts.
The outlook hinges on execution of its data center capacity pipeline to reverse losses. Risks include persistent negative earnings, high debt, and competitive pressures. Institutional sentiment is cautiously optimistic given the 54% average price target upside, but profitability improvement is critical for sustained momentum.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
